Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - JOHNSON & JOHNSON | acclarentexhibitninetynine.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
report (Date of earliest event reported): January 20,
2010
(Exact
name of registrant as specified in its charter)
|
New
Jersey
|
I-3215
|
22-1024240
|
|
(State
or Other Jurisdiction of Incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
One
Johnson & Johnson Plaza, New Brunswick, New
Jersey 08933
(Address
of Principal Executive Offices) (Zip Code)
Registrant’s
telephone number, including area code: 732-524-0400
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01. Other Events.
On
January 20, 2010, the Company issued a press release to announce the completion
of the acquisition by Ethicon, Inc., a subsidiary of the Company, of Acclarent,
Inc., a privately held medical technology company dedicated to designing,
developing and commercializing devices that address conditions affecting the
ear, nose and throat, for a purchase price of approximately $785
million. The transaction is expected to have a dilutive impact to the
Company's 2010 adjusted earnings per share of approximately $0.03 to
$0.04. The Company’s press release is attached to this Report as
Exhibit 99.1.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Johnson
& Johnson
|
|||
|
(Registrant)
|
|||
|
Date: February
5, 2010
|
By:
|
/S/ STEVEN
M. ROSENBERG
|
|
|
Steven
M. Rosenberg
|
|||
|
Secretary
|
|||